What's the role of Kupffer cells in non-alcoholic steatohepatitis?

October 31, 2008

Nonalcoholic steatohepatitis (NASH) is a disorder characterized by hepatic steatosis, inflammation and fibrosis with a risk of developing cirrhosis and hepatocellular carcinoma (HCC). The progression from simple steatosis to cirrhosis has been attributed to inflammatory cytokines such as tumor necrosis factor alpha (TNF-), oxidative stress and endotoxin, in combination with fatty degeneration due to insulin resistance. At present, histopathological examination of liver biopsy tissue is the only way to definitively diagnose NASH. The diagnosis of NASH is important in clinical hepatology, as this common disease is known to progress to hepatic cirrhosis and finally HCC.

A research article to be published on October 21, 2008 in the World Journal of Gastroenterology addresses this question. The research team was led by Tatsuhiro Tsujimoto from Nara Medical University of Japan.

Kupffer cells and hepatic sinusoidal function can be evaluated using the contrast effect in the liver parenchymal phase during CEUS examination using Levovist®, strongly implicating Kupffer cells in the pathogenesis of NASH. Reduced function or uneven distribution of Kupffer cells in the liver may play a part in this phenomenon, although this is no more than conjecture at this stage. In this study, authors investigated the contrast effect in the liver parenchymal phase of CEUS using Levovist®, as well as Kupffer cell dynamics and phagocytic activity.

The diagnosis of NASH is important in clinical hepatology, as this common disease is known to progress to hepatic cirrhosis and eventually to HCC. At present, histopathological examination of liver biopsy tissue is the only way to definitively diagnose NASH. When patients with NASH undergo CEUS examination using Levovist®, a reduced contrast effect is seen in the liver parenchymal phase. They investigated Kupffer cell dynamics and phagocytic activity using a rat NASH model.

This report shows the contrast effect in the liver parenchymal phase of CEUS using Levovist®, as well as detailed Kupffer cell dynamics and phagocytic activity in the rat NASH model. The results confirmed the effectiveness of CEUS examination in diagnosing NASH. Authors expect that the CEUS examination using Levovist® is useful screening examination which picks up NASH among fatty liver patients.
-end-
Reference: Tsujimoto T, Kawaratani H, Kitazawa T, Hirai T, Ohishi H, Kitade M, Yoshiji H, Uemura M, Fukui H. Decreased phagocytic activity of Kupffer cells in the rat nonalcoholic steatohepatitis model. World J Gastroenterol 2008; 14(39): 6036-6043 http://www.wjgnet.com/1007-9327/14/6036.asp

Correspondence to: Tatsuhiro Tsujimoto, MD, PhD, Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. tat-tyan@xa2.so-net.ne.jp Telephone: +81-744-223051 Fax: +81-744-247122

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection. It provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th of every month. The WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the title China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

World Journal of Gastroenterology

Related Cirrhosis Articles from Brightsurf:

Researchers discover gene that could decrease likelihood of developing alcoholic cirrhosis
Researchers at Indiana University School of Medicine are learning more about how a person's genes play a role in the possibility they'll suffer from alcoholic cirrhosis with the discovery of a gene that could make the disease less likely.

When liver cirrhosis is deadly
A study by an international team of researchers headed by Professor Jonel Trebicka from the Frankfurt University Hospital and funded by the foundation EF Clif, has discovered which patients are particularly at risk for acute-on-chronic liver failure.

Blood tests can predict the risk of liver cirrhosis
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology.

Universal gut microbiome-derived signature predicts cirrhosis
UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.

Strength training benefits patients with cirrhosis
Three hours of weekly strength training combined with protein supplements leads to both bigger and stronger muscles in patients with cirrhosis.

Women are not more likely to die of cirrhosis than men, despite fewer liver transplants
Prior studies suggested women might have higher mortality of cirrhosis of the liver than men.

Movement toward a poop test for liver cirrhosis
In a study of people with nonalcoholic fatty liver disease and their twins and other close relatives, UC San Diego researchers were able to diagnose liver cirrhosis simply by analyzing a person's stool microbes.

Gum disease treatment may improve symptoms in cirrhosis patients
Routine oral care to treat gum disease (periodontitis) may play a role in reducing inflammation and toxins in the blood (endotoxemia) and improving cognitive function in people with liver cirrhosis.

Alcohol-related cirrhosis deaths skyrocket in young adults
Liver disease deaths jumped by 65 percent in the United States, from 1999-2016, disproportionately affecting adults ages 25-34.

Researchers find a promising new approach for treating liver cirrhosis
In a study in The American Journal of Pathology, investigators report that treatment with aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma (PPARα/γ) agonist, reduced inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF)-α overproduction in cirrhotic rats with PH.

Read More: Cirrhosis News and Cirrhosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.